| The
Evolving Role of Platinums and Biologics in the Treatment of Lung Cancer |
|
Section
1 |
|
| The Role of Targeted Therapies in Lung Cancer | Martin
J. Edelman, MD Director, Medical Thoracic Oncology Associate Professor of Medicine University of Maryland Baltimore, MD |
| The Rationale for EGFR Inhibition in Advanced Lung Cancer | Alan
B. Sandler, MD Associate Professor of Medicine Vanderbilt University Medical Center Nashville, TN |
| EGFR Inhibition in Refractory/Resistant Patients with Advanced NSCLC | Anne
S. Tsao, MD M. D. Anderson Cancer Center Houston, TX |
| Early Stage NSCLC: The Role of Chemotherapy | Eric
Vallieres, MD Associate Professor of Thoracic Surgery University of Washington Seattle, WA |
| Discussion/Question & Answer Session #1 | |
| Close Window | |